Meta-analysis in The Lancet recommends statins for all diabetics, regardless of CV risk
A meta-analysis published in the January 12 issue of the presitigous journal, The Lancet, suggests that diabetics should receive cholesterol-lowerings drugs regardless of whether they have the signs of heart disease.
A team of UK researchers assessed the efficacy of statins in 18,686 diabetes patients in 14 randomized trials and found that the effects of statins were similar in those with and without diabetes, and were comparably effective in diabetes sufferers with and without vascular disease.
The Lancet study may help expand sales for this lucrative class of drugs, which includes Pfizer's Lipitor (atorvastatin), Novartis' Lescol (fluvastatin), Bristol-Myers Squibb's Pravachol (pravastatin), AstraZeneca's Crestor (rosuvastatin) and Merck & Co's Zocor (simvastatin).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze